Syros Pharmaceuticals (SYRS) Competitors

Syros Pharmaceuticals (NASDAQ:SYRS) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, community ranking, media sentiment and profitability.

Which has preferable earnings and valuation, SYRS or GLMD?

Galmed Pharmaceuticals has lower revenue, but higher earnings than Syros Pharmaceuticals. Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syros Pharmaceuticals	$386K	1.56	-$164.57M	-$3.03	-0.01
Galmed Pharmaceuticals	N/A	N/A	-$6.91M	-$16.66	-0.10

Does the media prefer SYRS or GLMD?

In the previous week, Galmed Pharmaceuticals had 1 more articles in the media than Syros Pharmaceuticals. MarketBeat recorded 1 mentions for Galmed Pharmaceuticals and 0 mentions for Syros Pharmaceuticals. Galmed Pharmaceuticals' average media sentiment score of 1.87 beat Syros Pharmaceuticals' score of 0.00 indicating that Galmed Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Syros Pharmaceuticals	Neutral
Galmed Pharmaceuticals	Very Positive

Do insiders & institutionals have more ownership in SYRS or GLMD?

91.5% of Syros Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. 12.3% of Syros Pharmaceuticals shares are owned by company insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Does the MarketBeat Community prefer SYRS or GLMD?

Galmed Pharmaceuticals received 75 more outperform votes than Syros Pharmaceuticals when rated by MarketBeat users. Likewise, 62.17% of users gave Galmed Pharmaceuticals an outperform vote while only 61.06% of users gave Syros Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Syros Pharmaceuticals	Outperform Votes 367 61.06%	Underperform Votes 234 38.94%
Galmed Pharmaceuticals	Outperform Votes 442 62.17%	Underperform Votes 269 37.83%

Is SYRS or GLMD more profitable?

Galmed Pharmaceuticals' return on equity of -28.75% beat Syros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syros Pharmaceuticals	N/A	-3,369.56%	-97.04%
Galmed Pharmaceuticals	N/A	-28.75%	-24.98%

Do analysts rate SYRS or GLMD?

Syros Pharmaceuticals currently has a consensus target price of $3.33, indicating a potential upside of 14,780.95%. Given Syros Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Syros Pharmaceuticals is more favorable than Galmed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syros Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.20
Galmed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Which has more volatility and risk, SYRS or GLMD?

Syros Pharmaceuticals has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Comparatively, Galmed Pharmaceuticals has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500.

Summary

Syros Pharmaceuticals and Galmed Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.